IGF-1 LR3 monograph

IGF-1 LR3

Overview

IGF-1 LR3 is a modified IGF-1 analog designed to reduce binding to IGF-binding proteins and extend biologic activity compared with native IGF-1. It is not an FDA-approved bodybuilding drug, and human clinical data for performance enhancement are very limited. Most practical use information online is anecdotal; the core biology is based on IGF-1/IGF-1R signaling rather than LR3-specific trials.

Pharmacokinetics & Mechanism

• Class: Recombinant insulin-like growth factor analog / peptide growth factor
• Mechanism of action: IGF-1 LR3 acts as an IGF-1 receptor agonist. Native IGF-1 binding to IGF1R triggers receptor tyrosine kinase activation, phosphorylation of IRS and SHC, and downstream PI3K/Akt and Ras/MAPK signaling that drives cell survival, proliferation, and differentiation; LR3 is engineered to reduce IGF-binding protein interaction, which increases functional availability and can prolong effective activity versus native IGF-1. LR3-specific human mechanism data are not well established.
• Target(s): Primary target: IGF1 receptor (IGF1R). Downstream signaling: IRS proteins, SHC, PI3K, Akt, Ras/MAPK, and related survival/proliferation pathways. Native IGF-1 also has cross-talk with insulin receptor isoforms at high exposures, but LR3-specific selectivity data in humans are not well established.
• Route(s) of administration: Typically subcutaneous injection in nonmedical use; research/experimental settings may also use other parenteral routes, but human performance data are not well established. Oral use is not biologically credible because peptide digestion destroys activity.
• Onset: Not well established for LR3 in humans. Anecdotally, users report acute effects within hours to days, but the meaningful anabolic/tissue effects are expected to be delayed and context dependent rather than immediate.
• Half-life: Native IGF-1 has a short free half-life in circulation, but binding proteins extend its physiologic residence. For LR3, the commonly cited effective half-life is substantially longer than native IGF-1, often described around 20-30 hours in community/vendor material, but this is not well established in rigorous human pharmacokinetic studies. Treat any precise LR3 half-life as uncertain.